Description Lipovisc * ophthalmic gel 10g 2mg / gdenominazionelipovisc, 2mg / g, gel ophthalmicococategory pharmacotherapeuticulture artificial and other indifferent preparations. Principles activicarbomer.ececcipienticetrimide, preservative; sorbitol; Medium chain triglycerides; sodiumhydhydroxyid (for pH correction); Water purified.Indicaziontraining Symptomatic of dried eye syndrome.contrain indications / EFF.Secondaripersensitivity to the active ingredient or to any of the excipients listed. Pussyla therapy of dry eye disorders requires an individual dosing regime. Based on the gravity and the intensity of the symptoms, instill a drop in the conjunctival sack 3-5 times a day for approximately 30 minutes before bedtime (to avoid sticky eyelids). Children and adolescents up to 18 years: the safety and efficacy of the medicine, to the recommended dosage for adults, were established on the basis of clinical experience, but they are not available clinical studies. Method of administration: Ophthalmic use. For the treatment of keratoconjunctivitis sicca generally sideve consult an ophthalmologist since, usually, therapy is long-term or chronic. A drop of adequate sizes siottiene keeping the tube in a vertical position above the eye during instillation.conservationNon keep at a temperature greater than 25 degrees c.avvertenzele contact lenses must be removed before administration can be applied 30 minutes after the Medicinal instillation. The drug can prolong the contact time of ophthalmic drugs applied by topical. Any ophthalmic drugs used in conjunction with this product must be administered 15 minutes before the product’s intulsion. If the skin dryness of the eye persist or worsen, the treatment must be interrupted and must be consulted an ophthalmologist. Interaction studies have been carried out. Inspecially adverse reactions have been classified in terms of frequency, using the following convention: very common ( > = 1/10); common (from> = 1/100 to <1/10); uncommon (from> = 1/1000 to <1/100); rare (from> = 1/10,000 to <1 / 1,000); Very rare (<1 / 10,000); Not note. Ocular diseases. Mail: Burning in the eyes, redness of the eyes, Eczema eyelid, feeling of foreign body in the eyes, conjunctivitis giant papillary, itching in the eye, feeling of sticky eyes, superficial keratetepunted, excessive tearing, blurred vision. These reactions may occur due to the preservative used (cetrimide) or as an effect of intolerance to one of the other components. A blurred view can occur after the medicinal product instillation due to its high viscosity. In clinical studies conducted with Lipovisc, a single non-serious topical eye-to-eye reaction (burning in the eyes) has occurred. Pediatric population: No special data have been reported. The suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk report of the medicinal product. Gravidance and Allatattamentonon have been performed studies. No data are available regarding the use of carbomer in pregnant women. Studies conducted on animals do not indicate a direct toxicity on reproductive function. However, as a precaution, it is preferable to avoid the use of the pharmodaging pregnancy. It is not known if the Carbino or its metabolites excreted in breast milk. The risk for newborns / infants may not be excluded. The decision must be taken whether to interrupt lactation or interrupt therapy / refrain from the therapy with the therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for women. Studies in fertility are not static concerned.